<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Response criteria for plasma cell leukemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Response criteria for plasma cell leukemia</h1>
<div class="graphic"><div class="figure"><div class="ttl">Response criteria for plasma cell leukemia</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Category</td> <td class="subtitle1">Bone marrow criteria*</td> <td class="subtitle1">Peripheral blood criteria*</td> <td class="subtitle1">Serological criteria<sup>¶</sup></td> <td class="subtitle1">Other criteria</td> </tr> <tr class="divider_bottom"> <td>Stringent complete remission</td> <td> <p>Bone marrow plasma cells &lt;5 percent</p> <p>and</p> No malignant plasma cell by flow cytometry</td> <td>No plasma cells in peripheral blood by flow cytometry</td> <td> <p>Negative serum and urine immunofixation</p> Normal serum FLC ratio</td> <td>Absence of extramedullary disease</td> </tr> <tr class="divider_bottom"> <td>Complete remission</td> <td>Bone marrow plasma cells &lt;5 percent</td> <td>No plasma cells in peripheral blood</td> <td>Negative serum and urine immunofixation<sup>Δ</sup></td> <td>Absence of extramedullary disease</td> </tr> <tr class="divider_bottom"> <td>Very good partial response</td> <td>Bone marrow plasma cells &lt;5 percent</td> <td>No plasma cells in peripheral blood</td> <td> <p>≥90 percent reduction of serum M-protein</p> <p>and</p> 24-hour urinary M-protein &lt;100 mg per 24 hours<sup>◊</sup></td> <td>Absence of extramedullary disease</td> </tr> <tr class="divider_bottom"> <td>Partial response</td> <td>Bone marrow plasma cells 5 to 25 percent</td> <td>Peripheral blood plasma cells from 1 to 5 percent</td> <td> <p>≥50 percent reduction of serum M-protein</p> <p>and</p> Reduction in 24-hour urinary M-protein by ≥90 percent and &lt;200 mg per 24 hours<sup>§</sup></td> <td>≥50 percent reduction in the size of extramedullary disease</td> </tr> <tr class="divider_bottom"> <td>Stable disease</td> <td colspan="4">Not meeting the criteria of either partial response or progressive disease</td> </tr> <tr class="divider_bottom"> <td>Progressive disease</td> <td>&gt;25 percent increase in plasma cells in a bone marrow aspirate or absolute increase ≥10 percent</td> <td>&gt;5 percent absolute increase in peripheral blood plasma cells</td> <td> <p>&gt;25 percent increase in the level of the serum monoclonal paraprotein with an absolute increase ≥5 g/L</p> &gt;25 percent increase in the 24-hour urinary light chain excretion with an absolute increase ≥200 mg/24 hours</td> <td> <p>Hypercalcemia</p> <p>Definite increase in lytic bone lesions</p> Definite increase in the size or number of extramedullary disease</td> </tr> <tr> <td>Relapse from complete remission</td> <td>More than 10 percent increase in bone marrow plasma cells</td> <td>Reappearance of peripheral blood plasma cells at any level</td> <td>Reappearance of original M-protein in serum and/or urine immunofixation</td> <td>Any extramedullary disease</td> </tr> </tbody></table></div><div class="graphic_footnotes">FLC: free light chain.<br/>* It is recommended that at least 200 leukocytes on blood smears and 500 nucleated cells on marrow smears be counted.<br/>¶ It should be maintained for a minimum of six weeks. In case of discrepancy or undetectable serological parameter, the patient must be classified according to bone marrow criteria.<br/>Δ If the serum and urine M-protein are unmeasurable, a normal serum kappa/lambda FLC ratio is also required.<br/><font class="lozenge">◊</font> If the serum and urine M-protein are unmeasurable, a ≥90 percent decrease in the difference between involved and uninvolved FLC levels is required instead of the M-protein.<br/>§ If the serum and urine M-protein are unmeasurable, a ≥50 percent decrease in the difference between involved and uninvolved FLC levels is required instead of the M-protein.</div><div class="graphic_reference">Reprinted by permission from: Macmillan Publishers Ltd: Leukemia. Fernández de Larrea C, Kyle RA, Durie BM, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013; 27:780. <a href="http://www.nature.com/leu" target="_blank">www.nature.com/leu</a>. Copyright © 2013.</div><div id="graphicVersion">Graphic 89246 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
